The biological activities of IGF-I and -II are mediated mainly by the type 1 IGF receptor (IGF 1R) and controlled by their interaction with soluble proteins, the IGF binding proteins (IGFBPs). Although there is a growing body of evidence that some IGFBPs may be cell surface-bound, published data concerning cell association of IGFBP-1 are scarce and none of them concern placental cells. The cell membranes used in this study were isolated from term human placentae. Detergent-solubilized membranes were shown to contain two types of IGF binding structures that were separated by gel filtration on a Sephadex G-100 column. Proteins in the first peak were eluted at V 0 (M r > 100 kD) and they bound IGF-I with greater specificity and affinity than IGF-II and insulin. Most likely, they represented the IGF 1R. Small proteins (M r » 45 kD) were eluted with the membrane proteins in the second maximum. They were able to bind IGF-I and IGF-II, but not insulin. The identity of these proteins was shown to be IGFBP-1 on the basis of their reaction with specific anti-IGFBP-1 antibodies. To the best of our knowledge, the existence of IGFBP-1 associated with human placental cell membranes has not been reported in the literature before. Colocalisation of IGFBP-1 with IGF 1R in cell membranes could provide efficient modulation of IGF 1R receptor-ligand interactions.
INTRODUCTION
The insulin-like growth factors, IGF-I and IGF-II, are polypeptides with structural homology to proinsulin, affecting growth, differentiation, and various metabolic processes in an endocrine and autocrine/paracrine fashion. The signalling of both IGFs is mediated by the type 1 IGF receptor (IGR 1R), a heterotetrameric glycoprotein composed of two ligand-binding a-subunits and two transmembrane b-subunits (M r 350 kD). It shares structural and functional homology with the well-characterized insulin receptor. 1 The IGF 1R binds IGF-I with high affinity, IGF-II with several fold lower affinity and insulin with more than 100-fold lower affinity. 2 IGF-II also binds to a type 2 IGF receptor (IGF 2R), a single-chain membrane-spanning glycoprotein (M r 300 kD), which is selective for IGF-II and has no affinity for insulin. Its role in IGF-II signal transduction is still a matter of debate. 3 Finally, the actions of the IGFs are modulated by a superfamily of six IGF-binding proteins (IGFBPs), IGFBP-1 through IGFBP-6, and a growing number of related proteins (IGFBP-rPs) whose physiological relevance has yet to be established. IGFBPs bind the IGFs with equal or even greater affinities than do the IGF receptors, and therefore are placed in a critical regulatory position between IGFs and their cell surface receptors. While some IGFBPs have been shown to inhibit IGF actions by preventing them from gaining access to the IGF receptors, others potentiate IGF actions by facilitating the ligand-receptor interaction. 4 Recent studies indicated that some IGFBPs have their own receptors that mediate IGF-independent actions. IGFBP-1 and IGFBP-2 contain intergrin recognition sequences, Arg-Gly-Asp (RGD), which is the minimum requirement for interaction with integrins on the cell surface. IGFBP-3 was shown to possess its own receptor and binds to heparin. 5 The aim of this work was to investigate the membrane-associated IGF binding structures in human placental cell membranes.
EXPERIMENTAL

Materials
Sephadex G-100 was obtained from Pharmacia Biotech AB, Sweden. Human IGF-I and IGF-II were from ICN Biomedicals, USA. Porcine insulin was from Novo Research Institute, Denmark. Na 125 I was supplied by Polatom, Poland. Goat anti-hIGFBP-1 antiserum was obtained from Diagnostic Systems Laboratories Inc., USA. All other employed chemicals were purchased from Sigma Chemicals, USA.
Tracer
IGF-I, IGF-II and insulin were iodinated by the chloramine T method. 6 The specific activities of the 125 I-labelled peptides were approximately 100 mCi/mg.
Preparation of placental membranes
Placental membranes were prepared by a modification of the procedure given by Perdue et al. 7 Term human placenta was collected immediately after delivery, placed in ice-cold 50 mM phosphate buffered saline (pH 7.5) and washed extensively with the same buffer. The placenta was dissected free from large vessels, amniotic and chorionic membranes. The remaining tissue was minced and homogenized in a polytron homogenizer with 5 volumes of 50 mM HEPES buffer (pH 7.5) containing 250 mM sucrose, 1 mM EDTA and 2 mM phenylmethylsulphonyl fluoride. The homogenate was centrifuged at 600´g for 15 min. The pellet was discarded and the supernatant centrifuged at 18 000´g for 30 min. The supernatant obtained was further centrifuged at 100 000´g for 60 min to yield a pellet designated as placental membranes. The crude membrane pellet was washed twice and finally resuspended in membrane buffer (50 mM HEPES, pH 7.5, containing 4 mM MgCl 2 ). Aliquots were stored frozen at -80 ºC.
Solubilization of placental membranes
Membranes (20 mg of membrane proteins) were solubilized for 2 h at 4 ºC in 5 mL of 2 % Triton X-100 in membrane buffer. After centrifugation at 100 000´g for 90 min, the insoluble pellet was discarded and the clarified extract (solubilizate) was divided into aliquots and stored frozen at -80 ºC until use.
The membrane protein concentration was determined by the method of Lowry, 8 and in Triton solubilizates by the method of Bradford. 9 
Gel filtration
Solubilized membrane proteins (1 mg) were incubated with 0.5 pmol 125 I-IGF-I (500 000 cpm) in the presence or absence of unlabelled ligands (65 pmol IGF-I, or 65 pmol IGF-II or 170 nmol insulin) at 4 ºC overnight and chromatographed in 50 mM sodium phosphate buffer containing 100 mM NaCl and 0.1 % Triton X-100 (pH 7.5) on a Sephadex G-100 column (1.8´60 cm). The flow rate was 20 mL/h. 1 mL fractions were collected and their radioactivity (cpm) measured in a g-counter (APEX Auto Gamma Counter, Micromedic Systems Inc.). The same experiments were performed with 125 I-IGF-II and 125 I-insulin as tracers. The column was calibrated using Blue Dextran 2000, egg albumin (EA, 45 kD) and IGF-I (7.5 kD).
Gel filtration was also used for the separation of the IGF binding structures. The solubilizate (4 mg of membrane proteins) was chromatographed without tracer and the proteins eluting between fractions 36 and 46 were collected and designated "peak 1 preparation", while those eluting between fractions 52 and 72 were designated "peak 2 preparation". The proteins present in peaks 1 and 2 were concentrated 2-5-fold and stored at 4 ºC. The proteins from the peak 1 preparation were used in competitive ligand binding assays, while the proteins from the peak 2 preparation were used in immunoaffinity interactions. The proteins from the peak 2 preparation (0.5 mL) were incubated with 0.5 pmol 125 I-IGF-I (or 125 I-IGF-II) in the presence or absence of goat anti-IGFBP-1 antiserum at 4 ºC overnight and analysed by gel filtration on the Sephadex G-100 column as described.
Competitive ligand binding assays
100 mg of membrane proteins (from placental membranes or solubilizate) or 0.1 mL of proteins from the peak 1 preparation were incubated with 17 fmol 125 I-IGF-I or -II (» 20 000 cpm) and increasing concentrations of unlabelled ligands (IGF-I, -II or insulin) in a final volume of 0.5 mL of membrane buffer containing 2 mg/mL BSA, at 4 ºC overnight. Triton X-100 at a final concentration of 0.04 % was present in all binding assays. Following incubation, 1.5 mL of 20 % (w/v) polyethylene glycol 6000 (PEG) was added. The tubes were vortex-mixed vigorously, left at 4 ºC for 20 min, then centrifuged (3000´g, for 40 min) and the supernatants were discarded. Precipitated radioactivity was measured in the g-counter. Nonspecific binding (NSB) was determined by incubating 125 I-IGF with binding buffer without membrane proteins. The specific binding was calculated as the difference between the total binding and the NSB. 10 The data were expressed as IC 50 (concentration of the competing ligand that inhibited labelled ligand-specific binding by 50 %) and analysed by the method of Scatchard. 11 
RESULTS
Detergent solubilized IGF-I binding structures from placental cell membranes were resolved into two components on a Sephadex G-100 column (Fig. 1a) . The first peak, designated peak 1, appeared at an elution volume (V e ) of 41 mL which was equivalent to the void volume of the column, V o . The second peak, designated peak 2, eluted at V e of 62 mL, which is the V e of egg albumin, indicating that proteins in this peak had a molecular weight of approximately 45 kD. Proteins in the second maximum bound approximately three times more 125 I-IGF-I than proteins in the first peak. The third radioactive maximum in the elution profile (V e » 99 mL) represented unbound 125 I-IGF-I. (Fig. 1a) The 125 I-IGF-I binding to the proteins present in peaks 1 and 2 was specific, as both peaks disappeared upon gel filtration in the presence of 65 pmol of unlabelled IGF-I. IGF-II was an equally potent inhibitor of the 125 I-IGF-I binding (results not shown), while insulin at a 2000-fold greater concentration could displace only about 30 % of the radioactivity initially bound in peak 1 (Fig. 1b) . This pattern of crossreactivity is characteristic of placental IGF 1R and it suggested the presence of this receptor in peak 1. 12 Proteins in peak 2, however, bound more 125 I-IGF-I in the presence of insulin than in its absence (Fig.  1b) . It is probable that insulin occupied a proportion of the IGF-I binding sites on IGF 1R, allowing 125 I-IGF-I to bind to a greater extent to proteins in peak 2.
As decidua is the primary source of IGFBP-1 in pregnant women 13 and as IGFBP-1 is the predominant IGFBP in amniotic fluid, 14 the interaction between specific anti-IGFBP-1 antibodies and proteins in peak 2 was tested. Proteins in peak 2 were separated by gel filtration, equilibrated with 125 I-IGF-I in the presence or absence of anti-IGFBP-1 antibodies and, again, analysed by gel filtration. The elution profiles obtained are given in Fig. 2 . In the presence of anti-IGFBP-1 antibodies the peak at a V e of 62 mL disappeared from the elution profile and a new peak, expected to represent the 125 I-IGF-I/IGFBP-1/anti-IGFBP-1 antibody complex, appeared at V o . The experiment was also performed with 125 I-IGF-II as a tracer and similar elution profiles were obtained, while 125 I-insulin did not interact at all (data not shown). These results strongly indicated the presence of IGFBP-1 in the placental membranes. The possibility that peak 2 reflected the presence of contaminating soluble IGFBP-1 was ruled out, since repeated washing of the membranes prior to solubilization did not alter the magnitude of the peak.
The displacement of 125 I-IGF-I from crude placental membranes, membrane solubilizates or proteins in peak 1, separated by gel filtration, by competitive binding assays with unlabelled IGF-I, IGF-II and insulin was examined and the IC 50 values obtained are summarized in Table I . The pattern of crossreactivity was again characteristic of the IGF The IC 50 values obtained could be attributed to the interaction of ligands with the IGF 1R, because IGFBP-1/ 125 I-IGF-I complexes were not precipitated by PEG (results not shown). Scatchard analysis of the IGF-I binding to solubilized membrane proteins resulted in a curvilinear plot, providing evidence that both high affinity and low affinity binding sites existed (Fig. 3) . The dissociation constant (K d ) that characterized high affinity interaction was estimated to be 0.08 nM, and the binding capacity ( from nonspecific binding. In binding studies using 125 I-IGF-I and proteins in peak 1 (IGF 1R), insulin in low doses caused enhancement of 125 I-IGF-I binding to IGF 1R compared to the degree of binding in the absence of this competitor, demonstrating that the affinity of IGF 1R is influenced by interaction with other proteins (Fig. 4) .
DISCUSSION
Two IGF-I binding species were detected in human placental cell membranes and solubilizates and separated by gel filtration. The first IGF-I binding structure bound IGF-I with high affinity (IC 50 = 0.05). The specific interaction could be inhibited by IGF-II and insulin in a pattern characteristic of placental IGF 1R. 12 The second site of 125 I-IGF-I (and 125 I-IGF-II) binding was shown to be IGFBP-1. Widely recognised as soluble proteins, IGFBPs have been recently shown to associate with cell surfaces and components of the extracellular matrix. 5 Specific binding of IGFBP-1 to the a5b1 integrin (fibronectin receptor) in Chinese hamster ovary cells has been demonstrated. 15 In this study evidence is provided that IGFBP-1 is associated with human placental cell membranes. However, it is premature to speculate about the nature of this association.
It has recently been postulated that IGFBP-1 is a key regulator of IGF-I activity within the local environment of the placenta. 16 IGFBP-1 is synthesised in decidual cells, while the highest levels occur in amniotic fluid. 13, 14 Therefore, it is reasonable to speculate that decidual IGFBP-1 is transported through the trophoblast cells of the placenta to the amniotic fluid. The mechanism of transport is still unknown.
It has been noted in this study that IGF-1, IGF-II and insulin bind with higher affinity to solubilized receptors compared to crude membranes and that the proteins in peak 1 (presumed to be IGF 1R) exhibited an even greater difference in their binding properties when separated from IGFBP-1 by gel filtration. One possible explanation of this phenomenon would be a conformational change in the receptor structure, due to the artificial experimental milieu, which resulted in a high-affinity state of the IGF 1R. 17 It should be noted that the insulin receptor does not exhibit a comparable change in properties following solubilization. 18 Data from our laboratory support an alternative hypothesis, that a competitive binder, IGFBP-1, positioned in the proximity of IGF 1R, in the placental cell membranes, regulates the affinity of IGF 1R for its ligands. The concept of an affinity regulator, whose activity might be modulated by physiological circumstances, although attractive, needs further investigation. IGF-I i IGF-II posti`u svoje biolo{ke efekte prvenstveno putem vezivawa za tip 1 IGF receptora (IGF 1R), a u interakciji izme|u ovih peptida i receptora posreduju specifi~ni rastvorni proteini, IGF vezuju}i proteini (IGFBPs). U literaturi je sve vi{e podataka o vezivawu pojedinih IGFBP za }elijske povr{ine, mada je malo radova koji se odnose na vezivawe IGFBP-1 za }elije. ]elijske membrane, koje su kori{}ene u ovom radu, izolovane su iz tkiva terminske humane placente. Nakon solubilizacije membrana, gel-filtracijom na Sephadex-u G-100 razdvojene su dve vrste proteina koje vezuju IGF molekule. Proteini u prvom maksimumu, eluirani u nultoj zapremini kolone (V o ), vezivali su IGF-I sa ve}om specifi~no{}u i afinitetom u pore|ewu sa IGF-II i insulinom i najverovatnije predstavqaju IGF 1R. U okviru membranskih proteina eluiranih u drugom maksimumu detektovani su mawi proteini (M r » 45 kD), koji su vezivali IGF-I i IGF-II, ali ne i insulin. Na osnovu wihove reaktivnosti sa anti-IGFBP-1 antitelima, utvr|eno je da se radi o IGFBP-1. Koliko je nama poznato, ovaj rad predstavqa prvu potvrdu prisustva IGFBP-1 u membranama placentnih }elija. Prisustvo molekula IGFBP-1 u blizini membranski usidrenog IGF 1R moglo bi obezbediti efikasnu modulaciju interakcija izme|u receptora i odgovaraju}eg liganda. 
